RecruitingPhase 3NCT04510597
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Studying Acquired cystic disease-associated renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SWOG Cancer Research Network
- Intervention
- Cytoreductive Nephrectomy(procedure)
- Enrollment
- 364 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2033
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
- Kingman Regional Medical Center, Kingman, Arizona, United States
- Banner University Medical Center - Tucson, Tucson, Arizona, United States
- University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
- Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
- PCR Oncology, Arroyo Grande, California, United States
- Sutter Auburn Faith Hospital, Auburn, California, United States
- Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States
- Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
- Keck Medicine of USC Buena Park, Buena Park, California, United States
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States
- Eden Hospital Medical Center, Castro Valley, California, United States
- Sutter Davis Hospital, Davis, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04510597 on ClinicalTrials.govOther trials for Acquired cystic disease-associated renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06882486Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic TherapyInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- RECRUITINGNANCT06907095Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGNANCT07461090Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost AnalysisMenoufia University
- RECRUITINGPHASE1NCT07195682A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07006688A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentServier Bio-Innovation LLC
- RECRUITINGPHASE1, PHASE2NCT07219576Retifanlimab and Ruxolitinib In Solid MalignanciesUniversity of California, San Diego
- RECRUITINGPHASE1, PHASE2NCT07239596Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell CarcinomSuzhou Suncadia Biopharmaceuticals Co., Ltd.
See all trials for Acquired cystic disease-associated renal cell carcinoma →